AAPL345.16+1.17 (+0.34%) ▲|ABBV283.70-1.11 (-0.39%) ▼|ABT102.40+1.89 (+1.88%) ▲|ACN250.63+10.37 (+4.32%) ▲|ADBE270.41+15.35 (+6.02%) ▲|AMAT382.87-26.07 (-6.38%) ▼|AMD515.87-36.85 (-6.67%) ▼|AMGN448.50+10.16 (+2.32%) ▲|AMT181.12+3.48 (+1.96%) ▲|AMZN252.83-9.54 (-3.64%) ▼|AVGO325.60-12.21 (-3.61%) ▼|AXP323.72+0.11 (+0.03%) ▲|BA189.87-2.41 (-1.25%) ▼|BAC50.94+0.16 (+0.31%) ▲|BKNG162.10+3.72 (+2.35%) ▲|BLK1,141.03-8.57 (-0.75%) ▼|BMY62.79+1.67 (+2.73%) ▲|BNY144.18-1.67 (-1.15%) ▼|BRK-B548.48+9.49 (+1.76%) ▲|C122.15-1.71 (-1.38%) ▼|CAT705.10-35.12 (-4.74%) ▼|CL96.83+3.43 (+3.67%) ▲|CMCSA22.88+0.80 (+3.62%) ▲|COF204.44-2.23 (-1.08%) ▼|COP144.88-0.79 (-0.54%) ▼|COST1,009.82+11.51 (+1.15%) ▲|CRM249.25+7.47 (+3.09%) ▲|CSCO104.56-2.71 (-2.52%) ▼|CVS93.99+1.21 (+1.30%) ▲|CVX224.37-2.41 (-1.06%) ▼|DE638.30+1.76 (+0.28%) ▲|DHR232.42-1.45 (-0.62%) ▼|DIS113.00+1.17 (+1.05%) ▲|DUK123.57+2.90 (+2.40%) ▲|EMR158.15-4.96 (-3.04%) ▼|FDX301.75+3.52 (+1.18%) ▲|GD346.66+1.95 (+0.57%) ▲|GE291.48-4.40 (-1.49%) ▼|GEV829.29-96.63 (-10.44%) ▼|GILD155.79+2.22 (+1.45%) ▲|GM76.95+0.84 (+1.10%) ▲|GOOG323.64-7.31 (-2.21%) ▼|GOOGL327.55-7.21 (-2.15%) ▼|GS891.71-13.01 (-1.44%) ▼|HD324.76+10.62 (+3.38%) ▲|HON215.50+0.77 (+0.36%) ▲|IBM249.07-2.40 (-0.95%) ▼|INTC87.75-5.21 (-5.60%) ▼|INTU355.65+20.04 (+5.97%) ▲|ISRG439.80+11.68 (+2.73%) ▲|JNJ266.77+8.99 (+3.49%) ▲|JPM334.54-0.65 (-0.19%) ▼|KO94.65+1.97 (+2.13%) ▲|LIN509.18+8.61 (+1.72%) ▲|LLY1,313.27+42.52 (+3.35%) ▲|LMT582.25+30.74 (+5.57%) ▲|LOW203.69+7.13 (+3.62%) ▲|LRCX235.46-25.35 (-9.72%) ▼|MA631.93+9.31 (+1.49%) ▲|MCD250.60+4.35 (+1.77%) ▲|MDLZ64.33+1.59 (+2.53%) ▲|MDT95.78+2.75 (+2.96%) ▲|META654.00-43.52 (-6.24%) ▼|MMM174.01-0.73 (-0.42%) ▼|MO75.39+1.56 (+2.11%) ▲|MRK152.09+2.21 (+1.47%) ▲|MS183.81-3.20 (-1.71%) ▼|MSFT526.09-6.86 (-1.29%) ▼|MU870.16-43.52 (-4.76%) ▼|NEE80.74+2.46 (+3.14%) ▲|NFLX67.23+2.19 (+3.36%) ▲|NKE38.25+0.72 (+1.92%) ▲|NOW156.61+3.49 (+2.28%) ▲|NVDA213.86-8.12 (-3.66%) ▼|ORCL126.23-2.90 (-2.25%) ▼|PEP137.97+3.27 (+2.43%) ▲|PFE30.27+0.42 (+1.39%) ▲|PG166.03+9.19 (+5.86%) ▲|PLTR199.03-2.69 (-1.33%) ▼|PM200.96+3.50 (+1.77%) ▲|QCOM175.40-2.57 (-1.44%) ▼|RTX191.82+0.22 (+0.11%) ▲|SBUX101.53+2.45 (+2.47%) ▲|SCHW92.34+0.70 (+0.76%) ▲|SO92.79+2.40 (+2.66%) ▲|SPG210.17+4.62 (+2.25%) ▲|T22.53+0.62 (+2.81%) ▲|TMO683.47-10.55 (-1.52%) ▼|TMUS157.52+3.77 (+2.45%) ▲|TSLA381.59-4.89 (-1.26%) ▼|TXN282.10-2.56 (-0.90%) ▼|UBER68.58+0.96 (+1.41%) ▲|UNH425.88+8.88 (+2.13%) ▲|UNP295.77+7.90 (+2.74%) ▲|UPS101.25+1.68 (+1.69%) ▲|USB59.89+0.84 (+1.41%) ▲|V414.18+6.33 (+1.55%) ▲|VZ44.59+1.03 (+2.36%) ▲|WFC83.08+0.66 (+0.80%) ▲|WMT120.13+2.33 (+1.98%) ▲|XOM176.13-1.97 (-1.10%) ▼|AAPL345.16+1.17 (+0.34%) ▲|ABBV283.70-1.11 (-0.39%) ▼|ABT102.40+1.89 (+1.88%) ▲|ACN250.63+10.37 (+4.32%) ▲|ADBE270.41+15.35 (+6.02%) ▲|AMAT382.87-26.07 (-6.38%) ▼|AMD515.87-36.85 (-6.67%) ▼|AMGN448.50+10.16 (+2.32%) ▲|AMT181.12+3.48 (+1.96%) ▲|AMZN252.83-9.54 (-3.64%) ▼|AVGO325.60-12.21 (-3.61%) ▼|AXP323.72+0.11 (+0.03%) ▲|BA189.87-2.41 (-1.25%) ▼|BAC50.94+0.16 (+0.31%) ▲|BKNG162.10+3.72 (+2.35%) ▲|BLK1,141.03-8.57 (-0.75%) ▼|BMY62.79+1.67 (+2.73%) ▲|BNY144.18-1.67 (-1.15%) ▼|BRK-B548.48+9.49 (+1.76%) ▲|C122.15-1.71 (-1.38%) ▼|CAT705.10-35.12 (-4.74%) ▼|CL96.83+3.43 (+3.67%) ▲|CMCSA22.88+0.80 (+3.62%) ▲|COF204.44-2.23 (-1.08%) ▼|COP144.88-0.79 (-0.54%) ▼|COST1,009.82+11.51 (+1.15%) ▲|CRM249.25+7.47 (+3.09%) ▲|CSCO104.56-2.71 (-2.52%) ▼|CVS93.99+1.21 (+1.30%) ▲|CVX224.37-2.41 (-1.06%) ▼|DE638.30+1.76 (+0.28%) ▲|DHR232.42-1.45 (-0.62%) ▼|DIS113.00+1.17 (+1.05%) ▲|DUK123.57+2.90 (+2.40%) ▲|EMR158.15-4.96 (-3.04%) ▼|FDX301.75+3.52 (+1.18%) ▲|GD346.66+1.95 (+0.57%) ▲|GE291.48-4.40 (-1.49%) ▼|GEV829.29-96.63 (-10.44%) ▼|GILD155.79+2.22 (+1.45%) ▲|GM76.95+0.84 (+1.10%) ▲|GOOG323.64-7.31 (-2.21%) ▼|GOOGL327.55-7.21 (-2.15%) ▼|GS891.71-13.01 (-1.44%) ▼|HD324.76+10.62 (+3.38%) ▲|HON215.50+0.77 (+0.36%) ▲|IBM249.07-2.40 (-0.95%) ▼|INTC87.75-5.21 (-5.60%) ▼|INTU355.65+20.04 (+5.97%) ▲|ISRG439.80+11.68 (+2.73%) ▲|JNJ266.77+8.99 (+3.49%) ▲|JPM334.54-0.65 (-0.19%) ▼|KO94.65+1.97 (+2.13%) ▲|LIN509.18+8.61 (+1.72%) ▲|LLY1,313.27+42.52 (+3.35%) ▲|LMT582.25+30.74 (+5.57%) ▲|LOW203.69+7.13 (+3.62%) ▲|LRCX235.46-25.35 (-9.72%) ▼|MA631.93+9.31 (+1.49%) ▲|MCD250.60+4.35 (+1.77%) ▲|MDLZ64.33+1.59 (+2.53%) ▲|MDT95.78+2.75 (+2.96%) ▲|META654.00-43.52 (-6.24%) ▼|MMM174.01-0.73 (-0.42%) ▼|MO75.39+1.56 (+2.11%) ▲|MRK152.09+2.21 (+1.47%) ▲|MS183.81-3.20 (-1.71%) ▼|MSFT526.09-6.86 (-1.29%) ▼|MU870.16-43.52 (-4.76%) ▼|NEE80.74+2.46 (+3.14%) ▲|NFLX67.23+2.19 (+3.36%) ▲|NKE38.25+0.72 (+1.92%) ▲|NOW156.61+3.49 (+2.28%) ▲|NVDA213.86-8.12 (-3.66%) ▼|ORCL126.23-2.90 (-2.25%) ▼|PEP137.97+3.27 (+2.43%) ▲|PFE30.27+0.42 (+1.39%) ▲|PG166.03+9.19 (+5.86%) ▲|PLTR199.03-2.69 (-1.33%) ▼|PM200.96+3.50 (+1.77%) ▲|QCOM175.40-2.57 (-1.44%) ▼|RTX191.82+0.22 (+0.11%) ▲|SBUX101.53+2.45 (+2.47%) ▲|SCHW92.34+0.70 (+0.76%) ▲|SO92.79+2.40 (+2.66%) ▲|SPG210.17+4.62 (+2.25%) ▲|T22.53+0.62 (+2.81%) ▲|TMO683.47-10.55 (-1.52%) ▼|TMUS157.52+3.77 (+2.45%) ▲|TSLA381.59-4.89 (-1.26%) ▼|TXN282.10-2.56 (-0.90%) ▼|UBER68.58+0.96 (+1.41%) ▲|UNH425.88+8.88 (+2.13%) ▲|UNP295.77+7.90 (+2.74%) ▲|UPS101.25+1.68 (+1.69%) ▲|USB59.89+0.84 (+1.41%) ▲|V414.18+6.33 (+1.55%) ▲|VZ44.59+1.03 (+2.36%) ▲|WFC83.08+0.66 (+0.80%) ▲|WMT120.13+2.33 (+1.98%) ▲|XOM176.13-1.97 (-1.10%) ▼|
16.1 C
New York
Thursday, October 22, 2026

Tag: drug

newsFORsourcecompanycontentinformation1releasesmarket

RxPreferred Launches My-RxP: Cutting Costs for Brand, Specialty, GLP-1, and Fertility Medications by Up to 60%

NASHVILLE, Tenn., July 16, 2025 /PRNewswire/ -- RxPreferred, a leading transparent pharmacy benefit administrator, is proud to announce the launch of My-RxP, an innovative medication...

Liviniti Technology Wins Platinum Pinnacle Award

Purpose-built, cloud-based technology enables full PBM transparency with complete visibility, advanced data analytics and a flexible approach NATCHITOCHES, La., July 16, 2025 /PRNewswire/ -- Liviniti,...

Leading Drug Delivery Conference PODD Announces its 15th Annual Agenda

The Conference Forum announces the 15th annual PODD Drug Delivery Conference's 2025 agenda and featured sessions. NEW YORK, July 16, 2025 /PRNewswire/ -- Today, PODD: Partnership...

Safi Biotherapeutics and Functional Fluidics Initiate Collaboration to Validate Health and Quality of Manufactured RBCs

Collaboration to support Safi IND data package for use of mRBCs in sickle cell disease chronic transfusions CAMBRIDGE, Mass. and DETROIT, July 16, 2025 /PRNewswire/...

Piccolo Medical, Inc. Receives FDA Clearance for 2nd Generation SmartPICC® technology

SAN FRANCISCO, July 16, 2025 /PRNewswire/ -- Piccolo Medical, Inc. (Piccolo), a leading innovator in vascular access technology, today announced it has received 510(k) clearance...

Evox Therapeutics Expands Scientific Advisory Board

Additional world-leading expertise stands to further accelerate the Company’s pipeline programs targeting rare neurodegenerative diseases 
Additional world-leading expertise stands to further accelerate the Company’s pipeline programs targeting rare neurodegenerative diseases

Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

[Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends,...

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Ultomiris Drug Market size & share revenue was valued at approximately USD 4.16 Billion in 2024 and is expected to reach USD 5.47 Billion in 2025 and is expected to reach around USD 64.12 Billion by 2034, at a CAGR of 31.52% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are AstraZeneca, Xencor, Inc., Chugai Pharmaceutical, Argenx, Alexion Pharmaceuticals, and others. 
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Ultomiris Drug Market size & share revenue was valued at approximately USD 4.16 Billion in 2024 and is expected to reach USD 5.47 Billion in 2025 and is expected to reach around USD 64.12 Billion by 2034, at a CAGR of 31.52% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are AstraZeneca, Xencor, Inc., Chugai Pharmaceutical, Argenx, Alexion Pharmaceuticals, and others.

Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors

TAIPEI and SAN DIEGO, July 15, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for...

Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully...

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for...

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for...

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 15, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for...

PHASE Scientific Expands INDICAID® Respiratory Portfolio with Exclusive U.S. Launch of Novel FebriDx® Test

FebriDx® is a first-in-class rapid test that differentiates between bacterial and non-bacterial respiratory infections, offering significant potential to address critical unmet needs in patient...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrug

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers